IMR Press / EJGO / Volume 26 / Issue 1 / pii/2005117

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Granzyme B as a prognostic marker of cervical intraepithelial neoplasia

Show Less
1 Department of Gynecology, UNIFESP (Universidade Federal de Sāo Paulo), Sāo Paulo (Brazil)
2 Department of Pathology, UNIFESP (Universidade Federal de Silo Paulo), Sāo Paulo (Brazil)
Eur. J. Gynaecol. Oncol. 2005, 26(1), 87–89;
Published: 10 February 2005
Abstract

Granzyme B (GrB) is a serine protease synthesized in T lympocytes (CTL), released after T-cell activation resulting from exoge­nous stimulation. With perforin, GrB discharges apoptotic signals to a target cell and therefore constitutes a marker to identify acti­vated CTL. We aimed to quantify GrB expression by immunohistochemistry staining in 12 tissue fragments of cervical carcinoma, 33 cervical intraepithelial neoplasias treated by LLTEZ and nine cervical pieces without disease. Activated cytotoxic lymphocyte mean values (20 HPF-400x) in both epithelial and stromal pars were 7.11 cells in tissue without neoplasia, 33.45 cells in cervical intraepithelial neoplasia and 139.75 cells in carcinoma samples, with a statistical difference between them. Comparative analysis in the CIN group showed an expressive difference between cases with disease recurrence (19.28 cells) and without recurrence (37.26 cells). Thus, the relation between number of activated CTLs found at the moment of treatment and clinical evolution determined in this study, suggest GrB use as a prognostic marker.

Keywords
Granzyme B
Cervical intraepithelial neoplasia
Prognostic marker
Immunologic marker
Share
Back to top